ALR Technologies Prepares January 2026 Relaunch of GluCurve Pet CGM Following Successful Manufacturing Tests
Key Insights
ALR Technologies completed internal manufacturing testing of the GluCurve Pet CGM (search), showing accuracy results comparable to leading veterinary blood glucose meters.
The company plans to relaunch the first and only continuous glucose monitoring system designed specifically for diabetic cats and dogs in Canada by January 2026.
Market estimates suggest potential demand of 150,000-300,000 units annually in Canada and 2-3 million units each in the United States and Europe.
ALR Technologies SG Ltd (search) announced the successful completion of internal manufacturing testing on its GluCurve Pet CGM (search), with plans to relaunch the veterinary diabetes monitoring system in the Canadian market by January 2026. The testing demonstrated accuracy results comparable to the leading veterinary blood glucose meter currently considered the gold standard by veterinarians.
First-of-Its-Kind Veterinary CGM Technology
The GluCurve represents the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. The pet-friendly continuous glucose monitor sensor attaches painlessly to animals and provides blood sugar readings every three minutes for up to 14 days. Pet owners can monitor readings through the GluCurve Pet CGM (search) app, while veterinarians access data via the ALRT Veterinary Web Portal to manage patients and adjust insulin dosing remotely or in-person.
Joe Stern, Head of Animal Health at ALRT, emphasized the unmet medical need in veterinary diabetes care: "You cannot prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature does not provide the data needed to properly dose insulin or see trends as a CGM would."
Substantial Market Opportunity
Based on diabetes prevalence studies and pet population surveys, ALRT estimates significant market potential for the GluCurve system. The company projects annual demand of 150,000-300,000 units in Canada, 2,000,000-3,000,000 units in the United States, and an additional 2,000,000-3,000,000 units across Europe.
Stern noted the strong interest from stakeholders: "We believe this is why we have received so much interest and demand for the GluCurve Pet CGM (search) from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like ours to manage diabetic pets."
Manufacturing Partnership and Validation Studies
The company has partnered with CGM Medical Technology Shenzhen Ltd (search) for manufacturing CGM units at the Foxconn (search) facility in Shenzhen. After two years of development work, ALRT is approaching the launch of what it describes as the "new and improved GluCurve Pet CGM (search)."
To further validate the device's performance, an independent non-inferiority study is scheduled for mid-December. This study will demonstrate the GluCurve's efficacy against the leading veterinary blood glucose meter when compared to a chemistry analyzer.
Rollout Strategy
At relaunch, Canadian veterinary clinics will be able to order directly from the official Canadian website at www.GluCurve.ca, while the company works with purchasing groups and corporations for additional buying options. The United States relaunch is planned for early Q2 2026 through a strategic relationship with a leading veterinary distributor, followed by global expansion throughout Europe, Australia, Asia, South America, and other international markets.